Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks

MLA

Lars Viktrup, et al. “Subcutaneous Tanezumab 2.5 MG or 5 MG for Patients with Osteoarthritis of the Knee or Hip: Onset and Maintenance of Efficacy over 24 Weeks.” Osteoarthritis and Cartilage, vol. 28, Apr. 2020, pp. S144–45. EBSCOhost, https://doi.org/10.1016/j.joca.2020.02.239.

APA

Lars Viktrup, R. Langford, Francis Berenbaum, Takaharu Yamabe, Naoki Isogawa, Serge Perrot, Rod Junor, Mark T. Brown, Francisco J. Blanco, S. Araki, William Carey, Kenneth M. Verburg, K. Miki, & Christine R. West. (2020). Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks. Osteoarthritis and Cartilage, 28, S144–S145. https://doi.org/10.1016/j.joca.2020.02.239

Chicago

Lars Viktrup, R. Langford, Francis Berenbaum, Takaharu Yamabe, Naoki Isogawa, Serge Perrot, Rod Junor, et al. 2020. “Subcutaneous Tanezumab 2.5 MG or 5 MG for Patients with Osteoarthritis of the Knee or Hip: Onset and Maintenance of Efficacy over 24 Weeks.” Osteoarthritis and Cartilage 28 (April): S144–45. doi:10.1016/j.joca.2020.02.239.